How TNXP (Tonix Pharmaceuticals Holding) Makes Money in 2026: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a biotech company like TNXP makes money is essential for investors and anyone interested in the business of biotechnology. In this post, we break down TNXP's quarterly income statement (Q3 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick TNXP Overview

TNXP operates as a clinical-stage biopharmaceutical company focused on developing therapeutics for nervous system disorders, including treatments for Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Revenue comes primarily from grant funding, collaboration agreements, and limited product sales in early-stage commercialization efforts. As a biotech firm in the development phase, TNXP relies heavily on non-dilutive funding sources like government grants while advancing its pipeline toward potential milestone payments and royalties.

Revenue Breakdown

• Total Revenue (Q3 2025): $3.29M (+16.6% YoY)
  • No detailed segment breakdown available; revenue primarily from grants and collaborations in neurology-focused programs.
  • Growth is powered by increased grant awards and partnership milestones amid pipeline progress.

Gross Profit and Margins

• Gross Profit: $1.92M (58.4% gross margin)
  • Cost of Revenue: $1.37M (-12.1% YoY)
  • TNXP maintains robust margins due to low variable costs in grant-funded R&D and scalable clinical trial structures.
• Most costs come from direct research costs, clinical trial materials, and manufacturing for investigational drugs.

Operating Income and Expenses

• Operating Income: Not reported (significant operating loss due to high expenses)
• Operating Expenses: $29.0M (+108.0% YoY, ~881% of revenue)
  • R&D: $9.29M (+1.9% YoY, 282.3% of revenue) — focused on advancing clinical trials for lead candidates like oxycodone for pain management and other neurology assets
  • SG&A: $25.7M (+233.5% YoY, 781.2% of revenue) — driven by expanded administrative support for regulatory filings, business development, and public company compliance
  • TNXP continues to prioritize innovation while expanding operations to support multiple Phase 2/3 trials.

Net Income

• Pre-Tax Income: Not reported (expected loss position)
• Income Tax: Not applicable (net operating loss carryforwards typical for biotech)
• Net Income: Not reported (overall net loss reflecting heavy R&D investment stage)
• TNXP converts a minimal portion of sales into profit due to early-stage development costs outweighing revenue, common in biotech pre-commercialization.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives TNXP's Money Machine?

• Grant and collaboration revenue: 100% of revenue from non-dilutive sources funding pipeline advancement.
• Pipeline progress: Multiple clinical programs in neurology, with Q3 revenue growth signaling successful grant captures.
• R&D investment: Heavy focus on clinical trials, consuming over 28% of revenue equivalent in spend.
• Future growth areas: Commercialization of late-stage assets like TNX-102 SL for fibromyalgia, though not yet profitable.

Visualizing TNXP's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially SG&A) taking the largest chunk.
• Even after large investments in R&D and operations, the structure highlights biotech's classic cash burn profile for growth.

Key Takeaways

• TNXP's money comes overwhelmingly from grants and collaborations
• High gross margins illustrate the power of TNXP's asset-light R&D model
• Heavy investment in clinical development, balanced by efficiency in core revenue capture
• Ongoing growth is driven by pipeline milestones and funding successes

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2026)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About TNXP's Income Statement

1. What is the main source of TNXP's revenue in 2025?

TNXP generates over 100% of its revenue from grants, collaborations, and early development funding. No significant product sales yet as programs remain in clinical stages.

2. How profitable is TNXP in Q3 2025?

TNXP reported a net loss position in Q3 2025, with operating expenses far exceeding $3.29M revenue, reflecting moderate profitability challenges driven by aggressive R&D scaling.

3. What are the largest expense categories for TNXP?

The biggest expenses on TNXP's income statement are operating expenses, particularly Sales, General & Administrative (SG&A) at $25.7M and Research & Development (R&D) at $9.29M in Q3 2025, as TNXP prioritizes clinical trial expansion and regulatory preparations.

4. Why does TNXP operate at a loss?

TNXP, despite generating $3.29M in revenue, posted significant operating losses exceeding $29M in expenses in Q3 2025. This is because TNXP aggressively invests in late-stage clinical trials and pipeline advancement, believing these will drive long-term growth—even if unprofitable today.

5. How does TNXP's effective tax rate compare to previous years?

TNXP's effective tax rate in Q3 2025 was not applicable (0% reported), consistent with previous years. This low rate is primarily due to net operating loss carryforwards and R&D tax credits common in clinical-stage biotech firms.